GSK gains after positive results for two lung cancer drugs
14/09/2026 08:25
BUZZ-GSK gains after positive results for two lung cancer drugs
** Shares of British pharmaceutical company GSK GSK.L rise 2.5% to 1,815p
** Co's lung cancer drug Jideytro met its main goal, with complete or partial tumour shrinkage in 94% patients
** Co also reports positive late-stage data showing Ris-Rez (licensed from Hansoh Pharmaceutical 3692.HK) cut the risk of death by 54% vs standard chemotherapy in relapsed small cell lung cancer
** As of last close, stock down 2.96% YTD
(Reporting by Anushka Chourasia in Bengaluru)
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion